Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists

Victoria M. Pratt, Larisa H. Cavallari, Andria L. Del Tredici, Houda Hachad, Yuan Ji, Ann Moyer, Stuart A. Scott, Michelle Whirl-Carrillo, Karen E. Weck

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity–associated genes and alleles.

Original languageEnglish (US)
Pages (from-to)746-755
Number of pages10
JournalJournal of Molecular Diagnostics
Volume21
Issue number5
DOIs
StatePublished - Sep 1 2019

Fingerprint

Molecular Pathology
Joints
Alleles
Warfarin
Pharmacogenetics
Gene Frequency
Genes
Pathologists
Cytochrome P-450 CYP2C9
Population

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Recommendations for Clinical CYP2C9 Genotyping Allele Selection : A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. / Pratt, Victoria M.; Cavallari, Larisa H.; Del Tredici, Andria L.; Hachad, Houda; Ji, Yuan; Moyer, Ann; Scott, Stuart A.; Whirl-Carrillo, Michelle; Weck, Karen E.

In: Journal of Molecular Diagnostics, Vol. 21, No. 5, 01.09.2019, p. 746-755.

Research output: Contribution to journalReview article

Pratt, Victoria M. ; Cavallari, Larisa H. ; Del Tredici, Andria L. ; Hachad, Houda ; Ji, Yuan ; Moyer, Ann ; Scott, Stuart A. ; Whirl-Carrillo, Michelle ; Weck, Karen E. / Recommendations for Clinical CYP2C9 Genotyping Allele Selection : A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. In: Journal of Molecular Diagnostics. 2019 ; Vol. 21, No. 5. pp. 746-755.
@article{89472c56b067448fad61630e83e39002,
title = "Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists",
abstract = "The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity–associated genes and alleles.",
author = "Pratt, {Victoria M.} and Cavallari, {Larisa H.} and {Del Tredici}, {Andria L.} and Houda Hachad and Yuan Ji and Ann Moyer and Scott, {Stuart A.} and Michelle Whirl-Carrillo and Weck, {Karen E.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jmoldx.2019.04.003",
language = "English (US)",
volume = "21",
pages = "746--755",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "5",

}

TY - JOUR

T1 - Recommendations for Clinical CYP2C9 Genotyping Allele Selection

T2 - A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists

AU - Pratt, Victoria M.

AU - Cavallari, Larisa H.

AU - Del Tredici, Andria L.

AU - Hachad, Houda

AU - Ji, Yuan

AU - Moyer, Ann

AU - Scott, Stuart A.

AU - Whirl-Carrillo, Michelle

AU - Weck, Karen E.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity–associated genes and alleles.

AB - The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity–associated genes and alleles.

UR - http://www.scopus.com/inward/record.url?scp=85069732173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069732173&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2019.04.003

DO - 10.1016/j.jmoldx.2019.04.003

M3 - Review article

C2 - 31075510

AN - SCOPUS:85069732173

VL - 21

SP - 746

EP - 755

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -